Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So is Tony an officer of these companies? Quetzal Capital Funding and Valley Forge. Are these his companies?
lizm67, how long have you been with DNAG? So previous management was caught between the dotcom bust? What about Retro's claim that Tony was part of multiple stocks? See #72157. Thanks.
OT: Precious, how come we don't see you anymore on the DNAG board?
retro, what other companies were tony involved in? can you provide links?
Frog,
It actually does answer my question. If what you're saying about the company is true, then why don't you contact the SEC?
I personally go through their filed SEC documents. It did look like when it first went public previous management really sucked. New management though slow, is making some changes. I guess we'll all find out soon.
I would have to disagree with you Frog. After the spin out occurs, they would have raised the captial needed. CD59 will generate revenue in 2008 and they will have money to fund PT401. Also the parent will own a part of the spin off with royalties back to the parent. I don't see how thats a bad thing.
I'm holding based on this. If Dutchess will willing to release DNAG assets for shares of a company that don't even exist yet, then it has to mean something. They might know something we don't know. A billion dollar hedge fund has faith in DNAG. I'm in too.
DNAPrint(R) Genomics Reaches Payment Agreement With Dutchess Private Equities Fund, Ltd.
Tuesday July 31, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Jul 31, 2007 -- DNAPrint® Genomics (OTC BB:DNAG.OB - News) today announced that it has reached a payment agreement with Dutchess Private Equities Fund, Ltd. ("Dutchess") whereby approximately $6 million in notes and incentive debentures may be paid in full by the issuance of stock and warrants in connection with a proposed spin-off of DNAPrint's wholly owned subsidiary, DNAPrint® Pharmaceuticals, Inc. ("Pharmaceuticals").
ADVERTISEMENT
Under the terms of the agreement, following the spin-off, Pharmaceuticals would issue up to 2 million shares of Pharmaceuticals' common stock to Dutchess as payment for amounts due under certain notes that were made by DNAPrint® Genomics. As full repayment for the Incentive Debentures, the Registrant would also issue a warrant for 2,000,000 shares of Pharmaceuticals' common stock to Dutchess which could be exercised at an exercise price of $0.01 per share (expiring July 31, 2012) If the balance on the Incentives Debentures at the time of the spin-off is less than $2,000,000, then DNAPrint will be deemed to have made a principal payment on the Notes in the amount of the shortfall. In order to complete the spin-off, Dutchess has agreed to release all the pharmaceutical, diagnostic and associated assets in exchange for the shares of Pharmaceuticals' common stock.
Effective immediately and until such time that the notes and incentive debentures are paid in full, the agreement calls for DNAPrint® Genomics, Inc. to pay Dutchess the sum of 80% of the royalty income generated by Pharmaceuticals within 45 days after the end of each calendar quarter, and 4% of all other cash received by DNAPrint® Genomics, Inc., from sales of goods or services during the preceding calendar quarter. All of these payments are credited towards the retirement of the debt.
"We are genuinely pleased to reach this agreement with Dutchess, which could settle its DNAPrint® Genomics debt in full with the planned spin-off of the DNAPrint® Pharmaceuticals division and help to ensure the stability of the parent Company's finances," stated President and Chief Executive Officer Richard Gabriel.
New genealogy sites offer DNA testing
http://www.msnbc.msn.com/id/21426919/
jaber jaws, as an investor for 7 years, what positive things have happened? obviously, theres still a lot of work ahead of us. what has gabriel said in his last speech about sec filing? i know dnag has not gone forward with a lot of things, but the funding has been limited for the past 7 years. there seems to be a good chance for listing on the euronext. if biofrontera a company with no revenue and just a pipeline, i don't see why dnag can't. they have some revenue and their pipeline is pretty robust. it also seems dna ancestry is becoming more known now. i haven't been in this stock long, so i can't speak for what richard has said in the past. if you don't mind listing them, i would like to research on it. and one thing that keeps coming back to me is dutchess. why would they release all dnag's assets for pharma shares if the spin off won't happen? i would assume a billion dollar hedge fund would know when to cut its losses. so if duthcess is willing to give them a chance, i am too.
Sept 20th presentations talks about EPO:
"And we want to also be able to see where it doesn't work and is there a relationship between the state of diabetes and the fact that our molecule or Erythropoietin doesn’t work on those patients, because we know that at least 3% to 5% of those patients are refractory to EPO treatment. This is how our molecule works. It’s much different than the standard EPO. And it has its own unique pattern set that is outside of the patents of Johnson & Johnson, Amgen and the rest of the crew."
http://seekingalpha.com/article/47832-dnaprint-genomics-the-wall-street-analyst-forum-presentation-transcript
thats fine. i didn't invest in this company cause of stockhlder or jevor.
It doesn't mean it was management. It could be Dutchess selling its shares.
The conference in Atlantis is this week, with Tony Frudakis as a speaker.
http://72.14.253.104/search?q=cache:8_aL_HehsqcJ:www.moffitt.usf.edu/ContentStore/Total%2520Cancer%2...
dgplexus, TA info:
Transfer Agent
Standard Registrar and Transfer Co., Inc.,
12528 South 1840 E.
Draper, UT 84020
(801) 571-8844
you might want to call the transfer agent and check since they have the most up to date info. most websites base their info on the sec filings. nasdaq.com had it at 630million when it was at 640million.
You can't trust anyone on a message board. I think most pump/bash a stock for their own interest. Very few are genuine posters. I hope no one here bought the stock based on posts. I would suggest reading PRs and SEC filings.
What happened to Precious and Stockhldr? Looks like we got some new longs here.
stockpicker1,
can you ask about the revenue from the bioserve agreemnt? and also the revenue from doggiedna? expected revenue from the 4 pharma for genotyping service? anticipated date to resolve the financing issue? thanks.
bigdrive,
I read the SEC filings and their potential pipeline. I agree with you that is a gamble. What I meant is that I'm not looking to hold for short term but long term. For me, its worth the money at this price. I know the company has left a bad impression to most past investors as reflected in the share price.
Chris, No stockhlder was not there. LOL...
If you guys search DNAG in other boards, you will see that it triggered a lot of techincal play boards. This was simply a chart play.
Bag8ger, from what I've learned is that either one or a group of them will buy in blocks triggering huge volumes. They usually buy in on proposed news releases. With an unsual large volumes, it will trigger alerts on day traders screen. Then day traders, looking at charts thinking its a good technical play will buy in fueling the momo. Once it starts to run, regular investors seeing a PR will think that something huge is going to happen and buy in thus fueling the momo even more. This is when the traders who initiated the run sell into it, and then day traders get out also. So now the regular investors lose their initial investment and get mad.
People need to know some people day trade penny stocks as a living. A few days ago CBPC was on a run too with a PR that came out, and now it dropped back down. During this whole week, I had my order in at .006 and refused to pay more because the run was not sustainable unless some PR came out. Most long term holders should know that today was just a presentation and that no new development will have been put out cause it would of been PR. Those investors who bought in based on today's presentation probably got burned. Like I said, I rather have slow steady climb based on the business than huge up/down swings. I am not a "trader" but an "investor".
Stockboy, I think the long time holders here were excited about the run up but I don't think it was them who hyped the stock up. This was simply a momo play. It triggered on a lot of day traders alert and was simply a technical play. Most day traders have left the building. The company is the same as it was a week ago. Those who bought on the company's technology will be rewarded, but as you can see most bought on the momo a couple days ago and got burned cause most are not day traders. Once they bought in, day traders sell and move on to another technical play.
I didn't think the run up was on news. Probably some momo players started the run. It was plastered all over the stock boards. It was just a technical play. Personally I'm not a chart reader. I bought in based on their technology. I rather have a steady slow climb then a big up swing and down swing. I'm just going to sit and wait on the Bioserve revenue and the Ancestry revenue. GLTA. Looks like I will be able to pick up more at .006 after all.
I don't see tomorrow as anything special. They're just making a presentation like they did in September right? Unless, he's going to put out some new information that he didn't do at the last one.
Is it possible that its a run up for tomorrow? It just weird that this is running on the same week that we have our conference.
OT stockhlder, what do you do?
stockhlder, .0075 is looking good. i was hoping to get some more at .006.
I relistened to the Wallst presentation on Sept 20. Richard does talk about the parent retaining an equity in the pharma but does not specify how much the parent will retain. He said that the parent will receive royaltys from the pharma through the life of the patents. Any opinions?
Question for the board: If when the spin off does take place, how much of the pharma company will the parent company control? Will they own over 50% of the pharma or will they own less equity in it?
stockboy, why would the new shares be worthless. DNAG (parent) will still have revenues and it just fromed a partnership with Bioserve. CD59 will be part of the parent. The parent will also "own" DNAP after the spin off which means it will own more than 50% of the spin off. So why would my shares be worthless?
Froggy, can you list below the dates that DNAG had promised either for market or development on each pipeline item but it did not happen? Thanks.
1) Ovanome -
2) PONV - Ondansetron – Chemo-
3) Statinome -
4) Melphalan/Topotecan –
5) Acenome –
6) BC-LOH – Breast Cancer
7) Xeliri/Xelox –
8) Diabetes – Pre-Diabetes and Diabetic Complications
9) PT-201 – Opthalmic Allergies
10) PT-202 – Nasal Allergies
11) PT-301 – Atopic Dermatitis
12) PT-401 - Super EPO Anemia Drug – Renal Failure
13) PT-501 – ADHD - Methylphenidate
14) PT-502 – Drug Addiction - Methylphenidate – Ritalin-like Compounds
15) PT-503 – Depression - Methylphenidate – Ritalin-like Compounds
16) Cancer Compounds – **TI inhibitors in-licensed, closing imminent…4Q05 (Khandaker Report)
Frog, so in their pipeline so have they promised in terms of marketing or developing or timeline that they have not met? what have they promised shareholders but did not follow through on? I know of one which is the reverse split that they promised would not happen? anything else?
stockboy, can you explain why the spinoff is a r/s? i don't get it. if we get shares for another company and still keep our shares of the parent, why is it a reverse split?
DNAG Pipeline:
Here is a list of DNAG's pipeline that I found. What have they promised would be marketed by now and fell through on? I guess one sure one was ovanome. Anything else?
DNAPrint Genomics - PRODUCTS PIPELINE
MILESTONES FOR FORENSICS AND CONSUMER MARKETS
ANCESTRYbyDNA 2.0….R/D 2000-01…4Q 2002 market…Mar2004*replaced w/ V2.5
ANCESTRYbyDNA 2.5….R/D 2003….Feb2004 market…Feb2005 Laptop Biochip System
ANCESTRYbyDNA 3.0….R/D 2005.…Test kit.- 2006 market?
EURO-DNA 1.0…..R/D 2003.....4Q 2004 market
DNAWitness 2.0….R/D 2002……2003 market… 2004*replaced w/ V2.5
DNAWitness 2.5 …R/D 2003...July 2004 market…Test kit - late 2005 ...global sales 2006
DNAWitness 3.0………R/D 2005 (3.0 to include eye color)…market 2006?
DNAWitness-Y…added to DNA Witness product…Aug 2005 market
DNAWitness-Mito…added to DNA Witness product…Aug 2005 market
EURO Witness 1.0……………..R/D 2004…….Feb2005 market
RETINOME 1.0 Eyecolor …R/D 2003....4Q 2004 market…Test kit - late 2005…global sales 2006
RETINOME HA Haircolor…….R/D 2004….2005-06 validate…..2007 beta test……..2008 market?
SKIN SHADE………………… R/D 2005-07……2008 market?
AMERIND 1.0…………………R/D 2005-06……2007 market?
Genetic Family Tree DB……… R/D 2004…….online 2005
Searchable Ancestry Genealogy DB…… R/D 2003….online 2004…expand 2005/06
Searchable PhotoAncestryDB (Forensics)… R/D 2003….. online 2004…expand 2005/06
DNA Database for Native Americans…develop 2003/2004….expand 2005/06
DNA Database for African-Americans…. develop 2005…expand 2006
3D Biometrics Imaging System for DNA fuzzy photo - Forensics –…Jun 2005
MILESTONES FOR PHARMACOGENOMICS - DIAGNOSTICS AND THERANOSTICS
Diagnostic Products - Predictive Drug Classifier Tests
1) Ovanome - Taxol/Carboplatin efficacy for Ovarian Cancer
* R/D 1998…Announced Mar 2000…Validation Studies 2002-2004
* Diagnostic Phase II - 2005…FDA-PMA 2Q06…Launch 2006
* Market Potential - $50 Million Dollars
2) PONV - Ondansetron – Chemo-nausea (DNAPrint/Moffitt)
* R/D 2003…Diagnostic Phase II - 2005/06…..FDA-PMA 4Q06…Launch 2007
* New - October 15, 2006 – Abstract/Presentation - Anesthesiology 2006; 105: A402
Single Nucleotide Polymorphisms Associated with Postoperative Nausea/Vomiting and Zofran Response
Jinhong Liu, M.D., Ph.D., Keith A. Candiotti, M.D., Tony Frudakis, Ph.D., Barbara L. Handelin, Ph.D., Hector Vila, M.D.
Department of Anesthesiology, H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida
* Market Potential - $500 Million Dollars
3) Statinome - Lipitor, Zocor, efficacy, liver, muscle adverse myalgia response
* R/D 1998/2004…Diagnostic Phase II - 2005/06…FDA-PMA 2Q07...Launch 2008
* Market Potential - $1 Billion Dollars
4) Melphalan/Topotecan – Multiple Myeloma (DNAPrint/Moffitt)
* R/D 2003…Diagnostic Phase I - 2005/08….FDA-PMA 1Q08…Launch 2009
* Market Potential - $50 Million Dollars
5) Acenome – Ace Inhibitors - Enalapril, Lisinopril efficacy, muscle, adverse cough
* R/D 1998/2004…Diagnostic Phase I - 2005/08 …FDA-PMA 2Q08...Launch 2009
* Market. Potential - $750 Million Dollars
6) BC-LOH – Breast Cancer (DNAPrint/Moffitt)
* R/D 2003… Diagnostic Phase I - 2004/08…FDA-PMA 3Q08…Launch 2009
* Market Potential - $400 Million Dollars
7) Xeliri/Xelox – Colon Cancer (DNAPrint/Moffitt)
* R/D 2003… Diagnostic Phase I - 2005/08…FDA-PMA 4Q08…Launch 2009
* Market Potential - $200 Million Dollars
8) Diabetes – Pre-Diabetes and Diabetic Complications
* R/D 2005... Diagnostic Phase I – 1Q06… FDA-PMA 1Q09…Launch 2010
* DNAPrint licensed diabetes diagnostics test from Harvard Medcal School – Jan 26, 2006
* Market Potential - $5 Billion Dollars
* Feb 14, 2006 - DNAPrint Pharmaceuticals Retains DOCRO for Development of Immunoassay to Better Detect Diabetic Vascular Complications. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint's recently in-licensed intellectual property relating to glycated CD59. "DOCRO is a leading CRO specializing in the commercialization of diagnostic technologies," commented Dr. Hector J. Gomez, MD, PhD…"DOCRO's proven formula for success has resulted in an unparalleled track record at the FDA with over seventy consecutive successful FDA submissions."
Theranostics Products – Drug and Drug Test Combinations
9) PT-201 – Opthalmic Allergies
* Phase II – 2Q06…FDA-NDA 4Q07…Launch 2008
* Market Potential - $50 Million Dollars
10) PT-202 – Nasal Allergies
* Phase I – 2Q06…FDA-NDA 4Q07…Launch 2008
* Market Potential - $50 Million Dollars
11) PT-301 – Atopic Dermatitis
* Phase I – 2Q06…FDA- NDA 2Q08…Launch 2009
* Market Potential - $600 Million Dollars
12) PT-401 - Super EPO Anemia Drug – Renal Failure
* License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA-NDA 2009…Launch 2010
* Market Potential - $2.5 Billion Dollars – Revised 3/14/06 - $11 Billion Dollars
* DNAPrint exclusive worldwide license to develop a Super EPO anemia drug for renal failure
* Consulting contract with Super EPO inventor/patent-holder to help DNAPrint develop Super EPO drug
* Contract for CRO to manufacture Super EPO drug for pre-clinical testing, ready Fall 2005 (completed)
* Sept 2005 – Super EPO drug begins pre-clinical testing. Production schedule remains on track
* TWST – “We expect to file a New Drug Application (NDA) by 2009 and a product launch somewhere around 2010.”
* Mar 14, 2006 – DNAPrint™ Genomics Pharmaceuticals Division Announces That Research on Development of Super EPO Drug for Anemia Market Shows Promising Early Results
* May 16, 2006 - DNAPrint Pharmaceutical Completes Computational Model to Guide Preclinical Development on Anemia Drug. DNAPrint announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division completed a pre-clinical, first generation computational model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia.
13) PT-501 – ADHD - Methylphenidate – Ritalin-like Compounds
* License Oct 2005….Pre-clinical 2005…FDA-NDA 2009…Launch 2010
* Market Potential - $4.6 Billion Dollars
* Oct 25, 2005 -- DNAPrint genomics, Inc. today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine….Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, (Decision Resources, Inc)….
*Dr. Froimowitz and DNAPrint genomics are working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.
* TWST - Drug addiction compound has actually been selected by the National Institute of Drug Abuse (NIDA) for further study.
* Mar 3, 2006 - DNAPrint announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. “In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
14) PT-502 – Drug Addiction - Methylphenidate – Ritalin-like Compounds
* License Oct 2005…. Pre-clinical 2005…FDA-NDA 2010…Launch 2011
* Market Potential - $500 Million Dollars
15) PT-503 – Depression - Methylphenidate – Ritalin-like Compounds
* License Oct 2005….Pre-clinical 2005…FDA-NDA 2011…Launch 2012
* New – July 17, 2006 - DNAPrint Genomics Selects PT-502 Lead Research Compound for Development of Drug for Treating Depression. DNAPrint Genomics, Inc. today announced it has confirmed positive results in an animal model for anti-depressant activity for its PT-502 lead compound being developed with the Massachusetts College of Pharmacy and Health Sciences.
* Market Potential - $7 Billion Dollars
16) Cancer Compounds – **TI inhibitors in-licensed, closing imminent…4Q05 (Khandaker Report)
Biofrontera’s Drug Pipeline:
17) BF 200 ALA - 5-aminolevulinic acid - for actinic keratosis – in Clinical Phase III 2006…Market 2008
18) BF-Derm1 - for antihistamine-refractory urticaria – in Clinical Phase II 2006…Market 2009
19) BF 37 - Atopic Dermatitis - for eczema skin rash - Clinical Phase II….Sept 2005…Market 2010
20) BF 200 ALA – Kondyloma – for epidermotropic human papillomavirus (HPV)…in Clinical Phase II…Market 2009
21) BF 200 ALA – VIN III – for vulvar intraepithelial neoplasia …in Clinical Phase II…Market 2009
22) 5-HT2B receptor antagonist - for migraine prophylaxis - in Preclinical 2005…Market ?
Other DNAPrint Studies
23) Immune System Deficiencies and Suppressants - Sirolimus, Tacrolimus, Mycophenolate
* R/D 2001…NYU?…. Fall 2005 - Elipsis Biotherapeutics – Crohn’s Disease and other immune system disorders
24) Acute Lymphocyte Leukemia (ALL)
* R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?…..
25) Cervical Cancer and Environmental Tobacco Smoke
* FAMRI Grant Feb 2003….2 year grant….Publication 2006?....
PARTNERS
* Forensics and Consumer Genealogy - Lynn Peavey, Orchid Biosciences, and ReliaGene Technologies
* Forensics – DNAPrint working with defense industry consultant, Defense Life Sciences, towards defense and homeland security applications…Aug 2005
MERGERS, ACQUISITIONS, and SUBSIDIARIES
* DNAPrint Pharmaceuticals Subsidiary – DNAPrint Genomics forms wholly owned pharmaceutical subsidiary focused on personalized medicine, DNAPrint Pharmaceuticals…Oct 12, 2005
* "We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products." Data Monitor and the Pharmaceutical Manufacturer's Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year.
* DNAPrint ACQUISITION – Trace Genetics…Acquired Jun 2005
* Trace Genetics – diagnostics specialists in genetic identity DNA analysis, with expertise in genetic genealogy, forensics, molecular diagnostics and population genetics
* Trace Genetics will do product testing, production, and sales for forensics and consumer genealogy while DNAPrint continues core drug discovery research and clinical trials for DNAPrint’s growing drug pipeline.
* DNAPrint ACQUISTION…Biofrontera AG…July 13, 2005
* DNAPrint Genomics Acquires 18% Interest In Biofrontera AG, a Small German Pharmaceutical Company
* Biofrontera has proprietary programs for gene expression analysis and has 3 drugs already in their pipeline
* Biofrontera just acquired a new drug (Sept 2005) and now has 4 drugs in their pipeline
* Biofrontera milestone: Biofrontera stated intentions to do an IPO stock offering in Europe.
* Sept 2005 – Biofrontera completes bond funding for $20 million euro. Biofrontera’s new IPO stock offering is on track within 9 months
* Sept 2005 – Biofrontera acquires new drug for Atopic Dermatitis for it’s drug pipeline
* DNAPrint ACQUISITION – Kenna Technologies, Inc…Acquired Oct 25, 2005
Kenna Technologies, Inc., expertise in computational biology. Kenna is an in-silico drug discovery company developing proprietary biological simulations that will improve and accelerate drug discovery and development. Kenna’s platform provides a new rationale for selecting drug targets, evaluating the activity of candidate compounds, and planning clinical trials for promising drug compounds.
* DNAPrint ACQUISITION – Elipsis Biotherapeutic Corporation…Acquired Dec 22, 2005
SARASOTA, Fla., Dec. 22, 2005 -- DNAPrint Genomics, Inc. today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael's Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn's disease) including last year's publications of the discovery of a gene for Crohn's disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders.
* Feb 21, 2006 - Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services For Record Quarter Of Revenues
<!--[endif]-->
* DNAPrint - Research Sponsorship Agreement with Mass.College of Pharmacy and Health Sciences - 8-K Jan 31, 2006
On January 31, 2006, the Registrant entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for sponsored research in connection with the synthesis and testing of certain (Ritalin) compounds as possible human medications for drug abuse, attention deficit hyperactivity disorder, and depression. The research will be conducted under the supervision of Dr. Mark Froimowitz. The Registrant had previously licensed exclusive rights to the compounds from Dr. Froimowitz on October 19, 2005 under an Exclusive Licensing Agreement. The sponsored research payments total $300,000 and will be paid in monthly installments of $25,000 over one (1) year.
---------
All drugs, projects, acquisitions, and other data listed in this DNAPrint pipeline may or may not be inclusive of all possible drugs, projects or acquisitions that DNAPrint may presently be involved in. Milestone dates are subject to change by DNAPrint Genomics.
johnny, so the only thing DNAG promised and did not deliver was the ovanome project then?
Frog,
I haven't been on this board that long. If you don't mind can you list what DNAG has promised and failed to deliver in the past? Thanks.
Precious, any plans for after retirement from the Army?
OT: Precious, are you still in the Army?
johnny, all the technologys you state DNAG as having are patented right? I read some of them but don't understand. Very technical.